Salivary Oxytocin as a Biomarker of Psychedelic Treatment

Salivary Oxytocin as a Biomarker of Psychedelic Assisted Psychotherapy in Patients With Major Depressive Disorder

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Inclusion Criteria:

• Age >=18 years-old
• MDD defined by DSM-V criteria, and resistant to treatment
• Ongoing classical psychotherapeutic treatment
• Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).

Exclusion Criteria:

• Psychotic or bipolar disorder
• High suicidal risk
• Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders
• Pregnancy or breastfeeding.